APO Research
Talk to an analyst

APO RESEARCH · REPORT

Disease Control and Prevention Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Disease Control and Prevention Vaccine Market Analysis and Forecast 2026-2032

22 December 2025209 pages

Choose your research edition.

Industry ResearchDisease Control and Prevention Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Disease Control and Prevention Vaccine Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Disease Control and Prevention Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Disease Control and Prevention Vaccine Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Disease Control and Prevention Vaccine Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Disease Control and Prevention Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Disease Control and Prevention Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Disease Control and Prevention Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Disease Control and Prevention Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Disease Control and Prevention Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Disease Control and Prevention Vaccine include GSK, Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Pfizer, Daiichi Sankyo, AstraZeneca PLC, Sinovac Biotech Ltd and Serum Institute of India Pvt. Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Disease Control and Prevention Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Disease Control and Prevention Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Disease Control and Prevention Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Disease Control and Prevention Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Disease Control and Prevention Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Disease Control and Prevention Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Disease Control and Prevention Vaccine Segment by Company

GSK

Takeda Pharmaceutical Company Limited

Sanofi

Johnson & Johnson

Pfizer

Daiichi Sankyo

AstraZeneca PLC

Sinovac Biotech Ltd

Serum Institute of India Pvt. Ltd

Panacea Biotec Ltd

Novavax Inc

Mitsubishi Tanabe Pharma Corporation

Merck & Co., Inc

Inovio Pharmaceuticals Inc

Emergent BioSolutions Inc

CSL Limited

Bharat Biotech International

Bavarian Nordic A/S

Astellas Pharma Inc

Abbott Laboratories

Disease Control and Prevention Vaccine Segment by Type

Live-Attenuated

Inactivated

Recombinant Sub Unit and Toxoid

Disease Control and Prevention Vaccine Segment by Application

Pediatric Vaccine

Adult Vaccine

Disease Control and Prevention Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Disease Control and Prevention Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Disease Control and Prevention Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Disease Control and Prevention Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Disease Control and Prevention Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Disease Control and Prevention Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Disease Control and Prevention Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Disease Control and Prevention Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Live-Attenuated Major Player Table 3. Inactivated Major Player Table 4. Recombinant Sub Unit and Toxoid Major Player Table 5. Global Disease Control and Prevention Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Pediatric Vaccine Major Player Table 7. Adult Vaccine Major Player Table 8. Disease Control and Prevention Vaccine Industry Trends Table 9. Disease Control and Prevention Vaccine Industry Drivers Table 10. Disease Control and Prevention Vaccine Industry Opportunities and Challenges Table 11. Disease Control and Prevention Vaccine Industry Restraints Table 12. Global Disease Control and Prevention Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Disease Control and Prevention Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Disease Control and Prevention Vaccine Market Share by Region (2021-2026) Table 15. Global Disease Control and Prevention Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Disease Control and Prevention Vaccine Market Share by Region (2027-2032) Table 17. Global Disease Control and Prevention Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Disease Control and Prevention Vaccine Revenue Market Share by Players (2021-2026) Table 19. Global Disease Control and Prevention Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Disease Control and Prevention Vaccine Key Players Headquarters & Area Served Table 21. Global Disease Control and Prevention Vaccine Players, Product Type & Application Table 22. Global Disease Control and Prevention Vaccine Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Disease Control and Prevention Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Disease Control and Prevention Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Disease Control and Prevention Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Disease Control and Prevention Vaccine Revenue Market Share by Type (2027-2032) Table 30. Global Disease Control and Prevention Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Disease Control and Prevention Vaccine Revenue Market Share by Application (2021-2026) Table 34. Global Disease Control and Prevention Vaccine Revenue Market Share by Application (2027-2032) Table 35. GSK Company Information Table 36. GSK Business Overview Table 37. GSK Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. GSK Disease Control and Prevention Vaccine Product Portfolio Table 39. GSK Recent Development Table 40. Takeda Pharmaceutical Company Limited Company Information Table 41. Takeda Pharmaceutical Company Limited Business Overview Table 42. Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Product Portfolio Table 44. Takeda Pharmaceutical Company Limited Recent Development Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sanofi Disease Control and Prevention Vaccine Product Portfolio Table 49. Sanofi Recent Development Table 50. Johnson & Johnson Company Information Table 51. Johnson & Johnson Business Overview Table 52. Johnson & Johnson Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Johnson & Johnson Disease Control and Prevention Vaccine Product Portfolio Table 54. Johnson & Johnson Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Disease Control and Prevention Vaccine Product Portfolio Table 59. Pfizer Recent Development Table 60. Daiichi Sankyo Company Information Table 61. Daiichi Sankyo Business Overview Table 62. Daiichi Sankyo Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Daiichi Sankyo Disease Control and Prevention Vaccine Product Portfolio Table 64. Daiichi Sankyo Recent Development Table 65. AstraZeneca PLC Company Information Table 66. AstraZeneca PLC Business Overview Table 67. AstraZeneca PLC Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AstraZeneca PLC Disease Control and Prevention Vaccine Product Portfolio Table 69. AstraZeneca PLC Recent Development Table 70. Sinovac Biotech Ltd Company Information Table 71. Sinovac Biotech Ltd Business Overview Table 72. Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sinovac Biotech Ltd Disease Control and Prevention Vaccine Product Portfolio Table 74. Sinovac Biotech Ltd Recent Development Table 75. Serum Institute of India Pvt. Ltd Company Information Table 76. Serum Institute of India Pvt. Ltd Business Overview Table 77. Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Product Portfolio Table 79. Serum Institute of India Pvt. Ltd Recent Development Table 80. Panacea Biotec Ltd Company Information Table 81. Panacea Biotec Ltd Business Overview Table 82. Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Panacea Biotec Ltd Disease Control and Prevention Vaccine Product Portfolio Table 84. Panacea Biotec Ltd Recent Development Table 85. Novavax Inc Company Information Table 86. Novavax Inc Business Overview Table 87. Novavax Inc Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Novavax Inc Disease Control and Prevention Vaccine Product Portfolio Table 89. Novavax Inc Recent Development Table 90. Mitsubishi Tanabe Pharma Corporation Company Information Table 91. Mitsubishi Tanabe Pharma Corporation Business Overview Table 92. Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Product Portfolio Table 94. Mitsubishi Tanabe Pharma Corporation Recent Development Table 95. Merck & Co., Inc Company Information Table 96. Merck & Co., Inc Business Overview Table 97. Merck & Co., Inc Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Merck & Co., Inc Disease Control and Prevention Vaccine Product Portfolio Table 99. Merck & Co., Inc Recent Development Table 100. Inovio Pharmaceuticals Inc Company Information Table 101. Inovio Pharmaceuticals Inc Business Overview Table 102. Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Product Portfolio Table 104. Inovio Pharmaceuticals Inc Recent Development Table 105. Emergent BioSolutions Inc Company Information Table 106. Emergent BioSolutions Inc Business Overview Table 107. Emergent BioSolutions Inc Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Emergent BioSolutions Inc Disease Control and Prevention Vaccine Product Portfolio Table 109. Emergent BioSolutions Inc Recent Development Table 110. CSL Limited Company Information Table 111. CSL Limited Business Overview Table 112. CSL Limited Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. CSL Limited Disease Control and Prevention Vaccine Product Portfolio Table 114. CSL Limited Recent Development Table 115. Bharat Biotech International Company Information Table 116. Bharat Biotech International Business Overview Table 117. Bharat Biotech International Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Bharat Biotech International Disease Control and Prevention Vaccine Product Portfolio Table 119. Bharat Biotech International Recent Development Table 120. Bavarian Nordic A/S Company Information Table 121. Bavarian Nordic A/S Business Overview Table 122. Bavarian Nordic A/S Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Bavarian Nordic A/S Disease Control and Prevention Vaccine Product Portfolio Table 124. Bavarian Nordic A/S Recent Development Table 125. Astellas Pharma Inc Company Information Table 126. Astellas Pharma Inc Business Overview Table 127. Astellas Pharma Inc Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Astellas Pharma Inc Disease Control and Prevention Vaccine Product Portfolio Table 129. Astellas Pharma Inc Recent Development Table 130. Abbott Laboratories Company Information Table 131. Abbott Laboratories Business Overview Table 132. Abbott Laboratories Disease Control and Prevention Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Abbott Laboratories Disease Control and Prevention Vaccine Product Portfolio Table 134. Abbott Laboratories Recent Development Table 135. North America Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 136. North America Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 137. North America Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Disease Control and Prevention Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Disease Control and Prevention Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 142. Europe Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 145. Europe Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 146. Europe Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Disease Control and Prevention Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 148. Europe Disease Control and Prevention Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 149. China Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 150. China Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 151. China Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 152. China Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Disease Control and Prevention Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Disease Control and Prevention Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 159. Asia Disease Control and Prevention Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 160. SAMEA Disease Control and Prevention Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 161. SAMEA Disease Control and Prevention Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 162. SAMEA Disease Control and Prevention Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 163. SAMEA Disease Control and Prevention Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 164. SAMEA Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. SAMEA Disease Control and Prevention Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 166. SAMEA Disease Control and Prevention Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Disease Control and Prevention Vaccine Image Figure 2. Global Disease Control and Prevention Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Disease Control and Prevention Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Live-Attenuated Image Figure 5. Inactivated Image Figure 6. Recombinant Sub Unit and Toxoid Image Figure 7. Global Disease Control and Prevention Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Disease Control and Prevention Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Pediatric Vaccine Image Figure 10. Adult Vaccine Image Figure 11. Global Disease Control and Prevention Vaccine Market Size (US$ Million) & (2021-2032) Figure 12. Global Disease Control and Prevention Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Disease Control and Prevention Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Disease Control and Prevention Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Disease Control and Prevention Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Disease Control and Prevention Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Disease Control and Prevention Vaccine Revenue Market Share by Type (2021-2032) Figure 19. Global Disease Control and Prevention Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Disease Control and Prevention Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Disease Control and Prevention Vaccine Revenue Market Share by Application (2021-2032) Figure 22. North America Disease Control and Prevention Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032) Figure 24. North America Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032) Figure 25. North America Disease Control and Prevention Vaccine Revenue Share by Country (2021-2032) Figure 26. United States Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Disease Control and Prevention Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032) Figure 31. Europe Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032) Figure 32. Europe Disease Control and Prevention Vaccine Revenue Share by Country (2021-2032) Figure 33. Germany Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Disease Control and Prevention Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032) Figure 43. China Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032) Figure 44. Asia Disease Control and Prevention Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032) Figure 46. Asia Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032) Figure 47. Asia Disease Control and Prevention Vaccine Revenue Share by Region (2021-2032) Figure 48. Japan Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Disease Control and Prevention Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032) Figure 56. SAMEA Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032) Figure 57. SAMEA Disease Control and Prevention Vaccine Revenue Share by Country (2021-2032) Figure 58. Brazil Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Disease Control and Prevention Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Live-Attenuated
  • Inactivated
  • Recombinant Sub Unit and Toxoid
Applications
  • Pediatric Vaccine
  • Adult Vaccine
Companies covered
  • GSK
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Daiichi Sankyo
  • AstraZeneca PLC
  • Sinovac Biotech Ltd
  • Serum Institute of India Pvt. Ltd
  • Panacea Biotec Ltd
  • Novavax Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Merck & Co., Inc
  • Inovio Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • CSL Limited
  • Bharat Biotech International
  • Bavarian Nordic A/S
  • Astellas Pharma Inc
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Disease Control and Prevention Vaccine Market by Type
  3. 1.2.1 Global Disease Control and Prevention Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Live-Attenuated
  5. 1.2.3 Inactivated
  6. 1.2.4 Recombinant Sub Unit and Toxoid
  7. 1.3 Disease Control and Prevention Vaccine Market by Application
  8. 1.3.1 Global Disease Control and Prevention Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Pediatric Vaccine
  10. 1.3.3 Adult Vaccine
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Disease Control and Prevention Vaccine Market Dynamics
  1. 2.1 Disease Control and Prevention Vaccine Industry Trends
  2. 2.2 Disease Control and Prevention Vaccine Industry Drivers
  3. 2.3 Disease Control and Prevention Vaccine Industry Opportunities and Challenges
  4. 2.4 Disease Control and Prevention Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Disease Control and Prevention Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Disease Control and Prevention Vaccine Growth Trends by Region
  3. 3.2.1 Global Disease Control and Prevention Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Disease Control and Prevention Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Disease Control and Prevention Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Disease Control and Prevention Vaccine Revenue by Players
  2. 4.1.1 Global Disease Control and Prevention Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Disease Control and Prevention Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Disease Control and Prevention Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Disease Control and Prevention Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Disease Control and Prevention Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Disease Control and Prevention Vaccine Players, Product Type & Application
  8. 4.5 Global Disease Control and Prevention Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Disease Control and Prevention Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Disease Control and Prevention Vaccine Tier 1, Tier 2, and Tier 3
5 Disease Control and Prevention Vaccine Market Size by Type
  1. 5.1 Global Disease Control and Prevention Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Disease Control and Prevention Vaccine Revenue Market Share by Type (2021-2032)
6 Disease Control and Prevention Vaccine Market Size by Application
  1. 6.1 Global Disease Control and Prevention Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Disease Control and Prevention Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK Disease Control and Prevention Vaccine Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Takeda Pharmaceutical Company Limited
  8. 7.2.1 Takeda Pharmaceutical Company Limited Company Information
  9. 7.2.2 Takeda Pharmaceutical Company Limited Business Overview
  10. 7.2.3 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Product Portfolio
  12. 7.2.5 Takeda Pharmaceutical Company Limited Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Disease Control and Prevention Vaccine Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Disease Control and Prevention Vaccine Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Disease Control and Prevention Vaccine Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Daiichi Sankyo
  32. 7.6.1 Daiichi Sankyo Company Information
  33. 7.6.2 Daiichi Sankyo Business Overview
  34. 7.6.3 Daiichi Sankyo Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Daiichi Sankyo Disease Control and Prevention Vaccine Product Portfolio
  36. 7.6.5 Daiichi Sankyo Recent Developments
  37. 7.7 AstraZeneca PLC
  38. 7.7.1 AstraZeneca PLC Company Information
  39. 7.7.2 AstraZeneca PLC Business Overview
  40. 7.7.3 AstraZeneca PLC Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca PLC Disease Control and Prevention Vaccine Product Portfolio
  42. 7.7.5 AstraZeneca PLC Recent Developments
  43. 7.8 Sinovac Biotech Ltd
  44. 7.8.1 Sinovac Biotech Ltd Company Information
  45. 7.8.2 Sinovac Biotech Ltd Business Overview
  46. 7.8.3 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Product Portfolio
  48. 7.8.5 Sinovac Biotech Ltd Recent Developments
  49. 7.9 Serum Institute of India Pvt. Ltd
  50. 7.9.1 Serum Institute of India Pvt. Ltd Company Information
  51. 7.9.2 Serum Institute of India Pvt. Ltd Business Overview
  52. 7.9.3 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Product Portfolio
  54. 7.9.5 Serum Institute of India Pvt. Ltd Recent Developments
  55. 7.10 Panacea Biotec Ltd
  56. 7.10.1 Panacea Biotec Ltd Company Information
  57. 7.10.2 Panacea Biotec Ltd Business Overview
  58. 7.10.3 Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Panacea Biotec Ltd Disease Control and Prevention Vaccine Product Portfolio
  60. 7.10.5 Panacea Biotec Ltd Recent Developments
  61. 7.11 Novavax Inc
  62. 7.11.1 Novavax Inc Company Information
  63. 7.11.2 Novavax Inc Business Overview
  64. 7.11.3 Novavax Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novavax Inc Disease Control and Prevention Vaccine Product Portfolio
  66. 7.11.5 Novavax Inc Recent Developments
  67. 7.12 Mitsubishi Tanabe Pharma Corporation
  68. 7.12.1 Mitsubishi Tanabe Pharma Corporation Company Information
  69. 7.12.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  70. 7.12.3 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Product Portfolio
  72. 7.12.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  73. 7.13 Merck & Co., Inc
  74. 7.13.1 Merck & Co., Inc Company Information
  75. 7.13.2 Merck & Co., Inc Business Overview
  76. 7.13.3 Merck & Co., Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Merck & Co., Inc Disease Control and Prevention Vaccine Product Portfolio
  78. 7.13.5 Merck & Co., Inc Recent Developments
  79. 7.14 Inovio Pharmaceuticals Inc
  80. 7.14.1 Inovio Pharmaceuticals Inc Company Information
  81. 7.14.2 Inovio Pharmaceuticals Inc Business Overview
  82. 7.14.3 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Product Portfolio
  84. 7.14.5 Inovio Pharmaceuticals Inc Recent Developments
  85. 7.15 Emergent BioSolutions Inc
  86. 7.15.1 Emergent BioSolutions Inc Company Information
  87. 7.15.2 Emergent BioSolutions Inc Business Overview
  88. 7.15.3 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Product Portfolio
  90. 7.15.5 Emergent BioSolutions Inc Recent Developments
  91. 7.16 CSL Limited
  92. 7.16.1 CSL Limited Company Information
  93. 7.16.2 CSL Limited Business Overview
  94. 7.16.3 CSL Limited Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  95. 7.16.4 CSL Limited Disease Control and Prevention Vaccine Product Portfolio
  96. 7.16.5 CSL Limited Recent Developments
  97. 7.17 Bharat Biotech International
  98. 7.17.1 Bharat Biotech International Company Information
  99. 7.17.2 Bharat Biotech International Business Overview
  100. 7.17.3 Bharat Biotech International Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Bharat Biotech International Disease Control and Prevention Vaccine Product Portfolio
  102. 7.17.5 Bharat Biotech International Recent Developments
  103. 7.18 Bavarian Nordic A/S
  104. 7.18.1 Bavarian Nordic A/S Company Information
  105. 7.18.2 Bavarian Nordic A/S Business Overview
  106. 7.18.3 Bavarian Nordic A/S Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Bavarian Nordic A/S Disease Control and Prevention Vaccine Product Portfolio
  108. 7.18.5 Bavarian Nordic A/S Recent Developments
  109. 7.19 Astellas Pharma Inc
  110. 7.19.1 Astellas Pharma Inc Company Information
  111. 7.19.2 Astellas Pharma Inc Business Overview
  112. 7.19.3 Astellas Pharma Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Astellas Pharma Inc Disease Control and Prevention Vaccine Product Portfolio
  114. 7.19.5 Astellas Pharma Inc Recent Developments
  115. 7.20 Abbott Laboratories
  116. 7.20.1 Abbott Laboratories Company Information
  117. 7.20.2 Abbott Laboratories Business Overview
  118. 7.20.3 Abbott Laboratories Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Abbott Laboratories Disease Control and Prevention Vaccine Product Portfolio
  120. 7.20.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Disease Control and Prevention Vaccine Revenue (2021-2032)
  2. 8.2 North America Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Disease Control and Prevention Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Disease Control and Prevention Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Disease Control and Prevention Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Disease Control and Prevention Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Disease Control and Prevention Vaccine Revenue by Country
  11. 8.6.1 North America Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Disease Control and Prevention Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Disease Control and Prevention Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Disease Control and Prevention Vaccine Revenue (2021-2032)
  2. 9.2 Europe Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Disease Control and Prevention Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Disease Control and Prevention Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Disease Control and Prevention Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Disease Control and Prevention Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Disease Control and Prevention Vaccine Revenue by Country
  11. 9.6.1 Europe Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Disease Control and Prevention Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Disease Control and Prevention Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Disease Control and Prevention Vaccine Revenue (2021-2032)
  2. 10.2 China Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Disease Control and Prevention Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Disease Control and Prevention Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Disease Control and Prevention Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Disease Control and Prevention Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Disease Control and Prevention Vaccine Revenue (2021-2032)
  2. 11.2 Asia Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Disease Control and Prevention Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Disease Control and Prevention Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Disease Control and Prevention Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Disease Control and Prevention Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Disease Control and Prevention Vaccine Revenue by Country
  11. 11.6.1 Asia Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Disease Control and Prevention Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Disease Control and Prevention Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Disease Control and Prevention Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Disease Control and Prevention Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Disease Control and Prevention Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Disease Control and Prevention Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Disease Control and Prevention Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Disease Control and Prevention Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Disease Control and Prevention Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Disease Control and Prevention Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Disease Control and Prevention Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Disease Control and Prevention Vaccine Revenue by Country
  11. 12.6.1 SAMEA Disease Control and Prevention Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Disease Control and Prevention Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Disease Control and Prevention Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst